[Remote] Key Accounts Manager, Northeast at Corcept Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Skills

Key technologies and capabilities for this role

Account ManagementRelationship BuildingHealthcare SystemsDisease AwarenessStrategic PlanningSales StrategyStakeholder EngagementCardio-metabolic DiseasesHypercortisolismCushing's Syndrome

Questions & Answers

Common questions about this position

What is the salary or compensation for the Key Accounts Manager role?

This information is not specified in the job description.

Is this Key Accounts Manager position remote or does it require travel or office presence?

This information is not specified in the job description.

What key skills or experiences are needed for the Key Accounts Manager role?

The role requires skills in developing and executing strategies for disease awareness, building relationships with healthcare system stakeholders, conducting educational programs, and driving protocol adoption for patient identification in hypercortisolism management.

What is the company culture like at Corcept Therapeutics?

Corcept fosters a collaborative environment dedicated to advancing cortisol modulation research, with a team and collaborators working together to unlock treatment possibilities for serious diseases across multiple areas.

What makes a strong candidate for the Key Accounts Manager position?

Strong candidates will have experience assessing healthcare system dynamics, engaging with specialists like endocrinologists and cardiologists, executing educational strategies, and driving system-wide changes for patient identification in hypercortisolism.

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free